What is ZymoChem?
ZymoChem operates at the intersection of synthetic biology and industrial chemistry, focusing on the development of Carbon Conserving (C2) microbes. These proprietary biological agents are engineered to convert renewable feedstocks into high-performance materials, effectively decoupling manufacturing from traditional fossil-fuel reliance. By optimizing the carbon efficiency of production cycles, ZymoChem addresses the critical need for sustainable, cost-competitive materials in the global supply chain.
The company's market position is defined by its multi-generational patent portfolio, which enables the production of bio-based goods without compromising on performance or scalability. As industries face increasing pressure to decarbonize, ZymoChem's technology offers a scalable solution for manufacturers seeking to integrate renewable inputs into their existing product lines, thereby fostering a more circular and sustainable economy.
How much funding has ZymoChem raised?
ZymoChem has raised a total of $25.4M across 2 funding rounds:
Angel/Seed
$350K
Series A
$21M
Angel/Seed (2016): $350K with participation from Breakout Labs
Series A (2024): $21M led by Lululemon, Breakout Ventures, Cavallo Ventures, KdT Ventures, GS Futures, and Toyota Ventures
Key Investors in ZymoChem
Breakout Labs
Breakout Ventures is an investment firm focused on early-stage companies that are developing research-based solutions to enhance human health and promote sustainability.
Toyota Ventures
Toyota Ventures is the early-stage venture capital arm of Toyota, investing in frontier technologies such as artificial intelligence, robotics, and climate technologies aimed at achieving carbon neutrality.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials.
What's next for ZymoChem?
With the successful closure of this major strategic investment, ZymoChem is poised to enter a phase of rapid operational expansion. The company is expected to prioritize the commercialization of its C2 microbe platform, focusing on scaling production capacity to meet the demands of global partners in the apparel and materials sectors. Strategic focus will likely shift toward optimizing supply chain integration and securing additional industrial partnerships to validate the economic viability of its bio-manufacturing processes at scale.
Furthermore, the involvement of diverse strategic investors suggests a multi-pronged approach to market entry, spanning consumer goods, agricultural technology, and climate-focused industrial applications. As ZymoChem continues to refine its proprietary technology, the firm remains a key player to watch in the broader transition toward a bio-based industrial future.
